Feasibility, performance, and acceptability of the wisebag™ for potential monitoring of daily gel applicator use in Durban, South Africa

AIDS and Behavior

Volumn 17, Issue 2, 2013, Pages 640-648

  Van Der Straten, Ariane ^a,b   Montgomery, Elizabeth ^a   Pillay, Diantha ^c   Cheng, Helen ^a   Naidoo, Anushka ^c   Cele, Zakhele ^c   Naidoo, Kalendri ^c   Hartmann, Miriam ^a   Piper, Jeanna ^d   Nair, Gonasagrie ^c  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adherence; Africa; Electronic monitoring; Microbicide gel

Indexed keywords

AGENTS USED INTRAVAGINALLY; TOPICAL ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MONITORING; EQUIPMENT DESIGN; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT ATTITUDE; PATIENT SATISFACTION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SOUTH AFRICA; STATISTICS;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; DOUBLE-BLIND METHOD; DRUG MONITORING; EQUIPMENT DESIGN; FEASIBILITY STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SATISFACTION; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SOUTH AFRICA; VAGINAL CREAMS, FOAMS, AND JELLIES;

MLCS; MLOWN;

EID: 84880918429     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-012-0330-y     Document Type: Article

References (16)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.
2. Weiss H, Wasserheit J, Barnabas R, Hayes R, Abu-Raddad L. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol. 2008;5(1):8.
3. Hendrix C, Minnis A, Guddera V, et al., editors. MTN-001: a phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. 18th conference on retroviruses and opportunistic infections. Boston; 2011.
4. Mâsse BR, Boily MC, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6(1):5.
5. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of PrEP trials for HIV prevention. AIDS. 2012;26(7):F13-9.
6. Tolley EE, Harrison PF, Goetghebeur E, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2010;14(5):1124-36.
7. Wallace A, Teitelbaum A, Wan L, Mulima M, Guichard L. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76(1):53-6.
8. Katzen LL, Fernández-Romero JA, Sarna A, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis. 2011;38(11):1050.
9. Moench TR, O'Hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis. 2012; Published Ahead-of-Print.
10. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378(9787):279-81.
11. Berg K, Arnsten J. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79.
12. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012.
13. Gengiah T, Mansoor L, Naidoo A, et al., editors. The CAPRISA 004 'Wisebag': enhancing adherence measurement in microbicide trials. microbicides 2010 conference. Pittsburgh; 2010.
14. Haberer J, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340-6.
15. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968-77.
16. Haberer J, Psaros C, Baeten J, et al. High adherence to oral PrEP is associated with lack of infections in an ancillary study of objective adherence monitoring and counseling among HIV discordant couples in Partners PrEP Study. 19th conference on retroviruses and opportunistic infections; 2012 March 5-8; Seattle.